Clinical trial

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04271475

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-07-07

PhasePHASE3

Study timeline

Study start (actual)2020-07-07Date precision: day

Registry last updated2025-06-27

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Chronic Thromboembolic Pulmonary Hypertensionunresolved

Interventions

MacitentanDRUG · verified · RxNorm: macitentan

PlaceboDRUG

Sponsors & collaborators

Actelionlead sponsor

Mapped research locations

SeoulSouth Korea4 BeijingChina4 ShanghaiChina3 IstanbulTurkey (Türkiye)3 BostonMassachusetts, United States2 MadridSpain2 LondonUnited Kingdom2 TaipeiTaiwan2 MoscowRussia2 Buenos AiresArgentina2 SofiaBulgaria2 AnkaraTurkey (Türkiye)2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04271475 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.